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 Estrogen receptor (ER) antagonists such as tamoxifen have been used 
successfully to treat ER+ breast cancers for more than 30 years.  Tamoxifen targets 
the ER and blocks the binding of estrogen thus preventing up-regulation of estrogen 
responsive genes and resulting in impaired cell proliferation.  Unfortunately, long 
term use of tamoxifen can result in resistance.  Previous studies have reported that 
naringenin, a flavanone, can inhibit cell proliferation and promote cell death in ER+ 
breast cancer cells. It has been reported that signaling pathways, such as mitogen 
activated protein kinase (MAPK), are up-regulated in tamoxifen resistant cells. 
Previous research suggests that naringenin inhibits the MAPK signaling pathways. 
For this study, I investigated the molecular targets of naringenin in tamoxifen-
resistant cells in order to determine the mechanism of action of naringenin in 
impairing cell proliferation and survival to gain further insight in the mechanism of 
naringenin action and its use as a possible therapeutic treatment. 
 To determine if naringenin is targeting the MAPK pathway, tamoxifen 
resistant MCF-7 breast cancer cells were treated with naringenin or U0126, a MAPK 
kinase inhibitor. Our studies show that while both U0126 and naringenin impair cell 
proliferation and viability the combination of U0126 and naringenin resulted in 
greater inhibition of cell viability than either compound alone.  It has been 
previously reported that naringenin can bind the ER. Our lab has also shown that 
naringenin inhibits ERα from entering the nucleus thus ERα displays a peri-nuclear 
localization pattern. Confocal microscopy revealed that in U0126 treated cells ERα 
displayed an even distribution across the cell as seen in tamoxifen resistant cells. 
This suggests that MAPK is not the only target of naringenin. Thus to identify other 
possible molecular targets of naringenin we screened phage display libraries. Our 
phage display studies identified several members of the E3 ubiquitin ligase family 
which are responsible for targeting proteins for ubiquitination thus degradation. E3 
ligases are important for proper regulation of protein levels within the cell. 
Together, our results suggest that MAPK is not the only target of naringenin. Instead 
these results suggest that naringenin could be targeting a more global protein such 
as E3 ligases and altering their activities thus altering the levels of target proteins 
involved in cell proliferation and survival. E3 ligases have been targeted by 
therapeutics for possible treatments in cancer and naringenin could be an effective 
therapeutic to target these E3 ligases. 
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CHAPTER I 
INTRODUCTION 
 
 
Breast cancer affects more women than any other type of cancer. The 
American Cancer Society estimated breast cancer to be 29% (226,870) of all new 
cases of cancer among women with approximately 40,000 deaths in the year 2012 
[1]. Cancer deaths reported from the years 1992-2008, ranked breast cancer first 
among women ages 20-59 years [1]. Current treatment involves surgery, 
chemotherapy, and endocrine therapy. Studies report early treatment with 
chemotherapy reduces odds of recurrence by 23% and death by 15%, while anti-
hormone treatment with tamoxifen for 5 or more years reduces annual recurrence 
40% and death by 30% in estrogen receptor (ER) positive cancer patients [2]. 
Estrogen and ER  
Seventy percent of breast cancer patients are ER+ (most often ER alpha). Cell 
growth in these cells is stimulated primarily by estrogen [3, 4]. The ER is a nuclear 
hormone receptor and transcription factor. Transcription of ER-regulated genes is 
mediated by 2 domains: the ligand-independent activation factor 1 (AF-1) domain 
and the ligand-dependent activation factor 2 (AF-2) domain[3]. The ER is often 
localized within the nucleus, however it can be found in the cytoplasm and at the 
membrane [5, 6]. The presence of ERs in cancer cells determines treatment. Tumors 
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lacking ER respond infrequently to endocrine therapy, whereas response rates of 50 
to 60 percent are observed in ER+ tumors [7]. 
Activation of ER 
 Activation of the ER can be achieved through ligand-dependent or 
independent pathways. Ligand-dependent activation of the ER depends on estrogen 
binding the ER. Following estrogen binding the ER forms a homodimer that 
translocates into the nucleus and binds to estrogen-responsive element (EREs) of 
target genes [8, 9].  
 In contrast, the ER  can also induce a non-genomic rapid response [3, 6, 9, 
10]. ERα can be found bound to the plasma membrane where the rapid, extra-
nuclear response is initiated [6, 10]. Once bound by estrogen, the ER is released 
from the membrane initiating the activation of  the mitogen-activated protein kinase 
(MAPK) pathway and the phosphoinositide 3-kinases (PI3K) pathways, both of 
which are pro-survival and growth [4, 6, 10]. ERα can also directly activate the 
epidermal growth factor receptor (EGFR), causing activation of the MAPK and PI3K 
pathways [4, 11, 12].  
 Ligand-independent activation of the ER (absence of E2) is a result of 
phosphorylation of multiple serine and tyrosine residues in the AF-1 and AF-2 
domains [3, 8, 13]. Growth factor receptors can activate the ER through several 
signaling pathways including the MAPK (Ras-Raf-MEK-ERK1/2) and PI3K(AKT) 
pathways  [11, 13, 14]. ERK (Extracellular signal-regulated kinases) 1 and 2 and 
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AKT (protein kinase B or PKB) phosphorylate serine 118 of the ER resulting in its 
activation [5, 11].  Ligand-independent activation of the ER has increased the need 
for treatments that target not only the ER but also these signaling pathways to block 
cell growth.  
ER and Breast Cancer 
In ER+ MCF-7 breast cancer cells, binding of estrogen to the ER not only 
activates transcriptional regulation of genes involved in cell proliferation but also 
regulates genes involved in cell survival  [15]. Estrogen responsive genes that are 
commonly upregulated in MCF-7 cells are Bcl-2, cyclin D-1, and survivin, all of which 
play a role in regulating cell proliferation and apoptosis [15]. 
The majority of breast cancer cells are dependent on estrogen stimulated growth 
which is why anti-estrogen treatments such as tamoxifen are so widely used [3, 5]. 
The most widely used anti-estrogens are the selective ER modulators (SERMs) [3]. 
SERMs allow for optimal function in all tissues where they function as estrogens in 
bone and cardiovascular tissues while functioning as anti-estrogens in breast and 
uterine tissue [3]. However, as previously stated the ER does not have to bind 
estradiol in order to become active. In the absence of estrogen (in the case of anti-
estrogen treatments where the ER is blocked, or in mutated ERs) growth factor 
signaling pathways such as MAPK and PI3K activate the ER.  
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Tamoxifen 
 The most widely studied and used SERM is tamoxifen, which has been in use 
since the early 1970s [16, 17].  Tamoxifen has been proven to be a safe and effective 
treatment for advanced breast cancer [16, 18]. Tamoxifen binds the estrogen 
receptor, preventing estrogens from binding, thus inhibiting the expression of 
estrogen-regulated genes, and blocking the G1 phase of the cell cycle causing a 
decrease in cell proliferation [16, 19]. Studies indicate that the optimal tamoxifen 
treatment duration needed to decrease reoccurrence and improve survival is 5 
years [16–19]. Unfortunately, the therapeutic benefits of tamoxifen are limited by 
acquired resistance [14, 20, 21].  Since multiple signaling pathways, such as the 
MAPK pathway, activate the ER, tamoxifen-resistant (Tam-R) cells have a 
heightened sensitivity to epidermal growth factor (EGF) and estradiol activation of 
MAPK as well as increased cross talk in proliferation pathways [20, 22, 23]. 
Activation of MAPK Signaling Pathway 
 ER+ Tam-R cell lines are reported to have constitutive activation of both the 
PI3K/AKT and MAPK pathways [4]. The MAPK cascades are important regulatory 
signaling pathways for cell proliferation, survival, and differentiation [24, 25]. The 
MAPK  pathway is often mutated in various cascade kinase proteins, including Ras 
(the most frequently mutated oncogene), often leading to over-expressed or 
constitutively active signaling proteins [24]. Abnormal activation of the MAPK 
pathway can result in alterations of controlled cell growth and proliferation as well 
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as survival and migration, which in cancer cells creates a growth advantage, 
metastasis, and is often associated with therapy resistance [26, 27].  
Naringenin 
 Naringenin is part of a large family of compounds found in fruits, vegetables, 
and many other plants [28–30]. Naringenin belongs to a group of natural substances 
known as flavanones. It has been shown that naringenin has an inhibitory effect on 
P450s, enzymes involved in biotransformation of various xenobiotics. Naringenin, 
along with other flavanoids, are linked to protective outcomes in regards to human 
health. For instance, flavanoids have been shown to reduce or protect against the 
development of endocrine tumors by binding the ER in individuals consuming a diet 
rich in flavanoids [6]. Furthermore, naringenin has been reported to induce 
apoptosis in different cancer cell lines containing ERα or ERβ (e.g., colon, breast, and 
uterus cancer cell lines)[6, 10]. 
 More importantly naringenin, like other natural and synthetic substances, 
has been identified as an endocrine disruptor (ED) and more specifically a 
xenoestrogen. Compounds within the category of EDs and xenoestrogens, such as 
naringenin, Bisphenol A (BPA) and quercetin, are able to bind to steroid receptors 
[6]. Many EDs often have structures that mimic natural steroid hormones (e.g., E2) 
and enable EDs to interact with ERs as agonists or antagonists [6]. The steroid like 
structure also allows the substance to easily move through cell membranes because 
it is lipophilic.  
6 
 
 Some flavanones alter hormone production and inhibit estrogen synthetase, 
a cytochrome p450 enzyme responsible for converting androgens to estrogens, such 
as estradiol, which have a major effect in the development of breast cancer [28, 30]. 
Naringenin has been shown to reduce glucose uptake and cell proliferation in MCF-7 
breast cancer cells [28, 29]. The exact mechanism of reduced proliferation and 
growth arrest of the cells is not understood. Our previous findings suggest that 
naringenin affects the MAPK signaling pathway which can result in decreased 
proliferation and cell survival [10]. It has also been reported that naringenin 
induces apoptosis in various cancer cells including MCF-7 breast cancer cells [10, 
31, 32]. 
Apoptosis  
 Apoptosis, programmed cell death, is a pathway that is stimulated by various 
stimuli and is regulated by caspases (cysteine aspartyl-specific proteases).  
Apoptosis is responsible for eliminating cells that have acquired excessive genomic 
damage, activated oncogenes, and cells that have progressed to malignancy [33]. 
Apoptosis can be promoted in response to ligands binding death receptors (intrinsic 
pathway) or by chemical/radiation damage (extrinsic pathway).  Intrinsic apoptotic 
pathways lead to the activation of the initiator caspase 8. Extrinsic apoptotic 
pathways cause loss of mitochondrial stability and the release of Cytochrome C, a 
central player in apoptosis [34, 35]. Cytochrome C, once released into the cytosol, 
leads to the activation of intiator caspase 9, by cleaving the caspase.  Active inititator 
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caspases lead to the cleaving of executioner caspases, such as caspases 3, 6, and 7. 
Active executioner caspases eventually cleave important cellular components, such 
as Poly ADP-ribose polymerase (PARP), resulting in cell degradation without 
inflammatory responses [34–36]. 
 
 
Figure 1. Overview of Apoptotic Pathways. Apoptosis is initiated through the 
activation of death receptors leading to the activation of caspase 8 or through DNA 
damage, exposure to chemical, or radiation causing the release of cytochrome C 
from the mitochondria, thus activating inititator caspases 9. The cleaving of 
inititator caspases 8 or 9 leads to the cleaving and thus activation of 
effector/executioner caspases 3,6, or 7 which then activates proteins such as PARP. 
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Naringenin and E3 Ligases 
Currently E3 ubiquitin ligases, a large family of proteins responsible for the 
regulation of many cellular proteins and thus biological processes, have been 
targeted by therapeutics [37, 38]. E3 ligases catalyze the ubiquitination of proteins 
targeted for degradation. E3 ligases regulate a variety of proteins involved in cell 
proliferation, cell survival, DNA repair and cell signaling [39, 40]. It has been 
reported that E3 ligases are often overexpressed and abnormally regulated in 
various cancers thus leading to abnormal regulation/degradation of cellular 
proteins and ultimately cancer development [37]. E3 ligases can act as oncogenes 
(XIAP, MDM2 and HUWE1) or tumor suppressors (BRAC1, Fbw7, and CHIP) 
depending on the type of ligase and cell type [39].  
Naringenin and MCF-7 Cells 
Our lab has generated a tamoxifen resistant (Tam-R) MCF-7 cell line. This cell 
line, unlike the tamoxifen sensitive MCF-7 cell line, continues to grow in the 
presence of tamoxifen (measured by flow cytometry). The addition of naringenin 
has been shown to reverse proliferation in the Tam-R cells. Furthermore, the Tam-R 
cells exhibited an up-regulation of the MAPK pathway which could also be reversed 
with naringenin.  
We also found that in tamoxifen resistant cells ERα exhibits a change in 
localization when compared to the tamoxifen sensitive MCF-7 cell line. ERα is 
distributed throughout the cell in MCF-7 cells (tamoxifen sensitive) and is found in 
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the nucleus when treated with tamoxifen. The Tam-R cell line has an even 
distribution of ERα across the cell similar to that found in untreated MCF-7 cells.  
However, upon treatment of the Tam-R cells with naringenin, the ERα localization 
becomes peri-nuclear. This suggests that naringenin is capable of changing the 
localization of ERα. Furthermore, naringenin and tamoxifen may work 
synergistically in Tam-R cells and could be even more effective in tamoxifen 
sensitive MCF-7 cells. The goal of this study is to identify the possible targets of 
naringenin in order to gain a greater understanding of the mechanism(s) involved in 
how naringenin affects MCF-7 cells proliferation and survival. 
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CHAPTER II 
MATERIALS AND METHODS 
Materials 
MCF-7 ER+ breast cancer cells (HTB-22) were purchased from ATCC. 
 Dulbecco’s Modified Eagle Medium was purchased from Gibco (11885).  Charcoal-
stripped fetal bovine serum (F6765), naringenin (N5893) and 4-OH-tamoxifen 
(H7904) was purchased from Sigma Aldrich. Antibodies for ERK 1/2 (9102), p-ERK 
1/2 (9101S), AKT (9272), p-AKT (4060S), Caspase 7 (9492P), PARP (9542P) and 
U0126 (9903) were purchased from Cell Signaling. Guava Via-Count Reagent (4000-
040) was purchased from Millipore. Actin antibody (ab3280) was obtained from 
Abcam.  Anti-ERα antibody (HC-20) was purchased from Santa Cruz biotechnology. 
AlexaFluor 488 conjugated Goat anti-Rabbit secondary antibody (111-545-003) was 
obtained from Jackson ImmunoResearch. Anti-mouse (A-4416) and anti-rabbit (A-
6154) horseradish peroxidase conjugated secondary antibodies were purchased 
from Sigma Aldrich.  The enhanced chemiluminescence (ECL) detection kit E-1119-
20) was from BioExpress. Ph.D-7 Phage display peptide library (E8102L) was 
purchased from New England BioLabs. QIAprep spin M13 kit (27704) was 
purchased from Qiagen Sciences.
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Cell Culture 
 Tam-R cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM)
supplemented with 10% charcoal-stripped FBS (Sigma Aldrich F6765) , 0.01 mg/mL 
bovine insulin, and 100 U/mL penicillin/streptomycin. Tam-R cells were maintained 
by adding 100nM of tamoxifen. Cells were maintained at 37° C and 5% CO2. Media 
was replaced every two days and cells were passaged at 80% confluency.    
Immunoblot 
 Protein extracts from various MCF-7 treatments were subjected to 10% SDS-
PAGE and then transferred overnight to an Immobilon-P membrane (Millipore IPFL 
00010).  The membrane was incubated with the specific primary and secondary 
antibodies and visualized using enhanced chemiluminescent (ECL) and a Bio-Rad 
ChemiDoc XRS. The bands were quantified using densitometric analysis using 
Quantity One analysis software.  
Flow Cytometry 
 MCF-7 cells were collected and centrifuged for 5 min at low speed (5), and 
the pellet was resuspended in 1x PBS.  Guava Via-Count Reagent was added to cells 
at a 1:20 or 1:10 dilution and incubated for five min at room temperature in the 
dark. Guava easy-Cyte Flow Cytometry was used to determine the percentage of 
viable, mid-apoptotic, and dead cells. Values were analyzed by guavaSoft software. 
 
12 
 
Confocal/ ER Localization 
 MCF-7 cells were grown on cover slips. Cover slips were washed with 1xPBS 
twice. Cells were fixed with 3.7% paraformaldehyde for 15 min, washed twice with 
1xPBS and then permeabilized for 5 min in Triton-X (0.25% in 1xPBS). Cover slips 
were blocked in a 5% goat serum (Jackson ImmunoResearch 005-000-121) - 1% 
BSA (MP, 81-00-33) - 1xPBS solution for 15 min. Cover slips were then incubated 
with anti-ERα primary antibody (1:100) for 1 h at room temperature. Cover slips 
were washed with 1xPBS then incubated with secondary antibodies (1:100 
dilutions) for 45 min at room temperature. Cover slips were washed then stained 
with DAPI (1:1000) for 5 min. After the final washes, coverslips were mounted in 
one drop of Dako mounting medium (S3023) and viewed by confocal microscopy.  
Phage Display 
 A random combinational constrained seven amino acid library (Ph.D.-C7CTM) 
was propagated in E. coli ER2738 cells. Naringenin was immobilized to a plate with 
0.1M NaHCO3 (pH 8.6) overnight at 4⁰C in a humidified container. A 100-fold 
dilution of phage (approximately 2x1011) were added to the plate, incubated and 
washed with TBST (TBS + 0.1% [v/v] Tween-20). After washing, the bound phage 
was eluted with 5% naringenin. Eluted phage was amplified by infecting ER2738 
bacterial cells and subjected to three more rounds of selection on an immobilized 
naringenin plate. The fourth eluate was plated with ER2738 on LB plates. Twelve 
random colonies were picked and purified using a Qiagen Phage mini prep kit 
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before sequencing. The same procedures were carried out for a twelve amino acid 
library (Ph.D.-12). 
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CHAPTER III 
RESULTS 
 
 
 Previous studies in our lab have shown that naringenin inhibits cell 
proliferation as a result of decreased cell viability. It has also been shown in our lab 
that naringenin inhibits ERK1/2 expression and phosphorylation and ERα 
translocation from the cytosol into the nucleus. These findings suggest that 
naringenin’s effects on cell proliferation, viability, and ERα localization could be a 
result of inhibition of ERK1/2 phosphorylation and expression. In this study I 
wanted to determine if the inhibition of ERK1/2 could account for all of naringenin’s 
effects on MCF-7 breast cancer cells. 
Naringenin is a Weak Inhibitor of ERK1/2 
 This study aims to determine if ERK1/2 is the primary target of naringenin in 
MCF-7 cells. I wanted to determine if the previously observed effects of naringenin 
in MCF-7 breast cancer cells could be accounted for by the inhibition of ERK1/2 
phosphorylation. It has already been shown that naringenin inhibits the 
phosphorylation of ERK1/2 in charcoal-stripped medium. While charcoal-stripping 
of serum removes estrogen, it also removes other lipophilic compounds as well as 
growth factors that are involved in promoting cell proliferation and survival. 
Therefore, the use of charcoal-stripped medium allowed us to study the effects of 
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naringenin in an estrogen independent environment. We used Tam-R MCF-7 cells 
which have estrogen independent cell proliferation. 
We compared the effects of naringenin and U0126, a known inhibitor of 
ERK1/2 phosphorylation on ERK1/2 expression and phosphorylation. To determine 
if U0126 elicits the same effect as naringenin on ERK1/2, we treated tamoxifen 
resistant MCF-7 cells with naringenin, U0126, and a combination of both for 24 h, 48 
h, and 4 days.  
The expression level and phosphorylation status of ERK1/2 were assayed 
using immunoblot analysis. The protein bands were quantified and normalized to 
the control group (untreated tamoxifen resistant MCF-7 cells). Our data confirmed 
that naringenin is an inhibitor of ERK1/2 phosphorylation at all the time points (Fig 
2A). However, when compared to the U0126 treatment, naringenin appears to be a 
weak inhibitor of ERK1/2 (Fig 2A). Phosphorylated ERK1/2 was undetectable in the 
U0126 alone and the combination treatment at all time points thus U0126 
significantly impaired the phosphorylation of ERK1/2 after 24 h and maintained 
this effect when compared to the control (Fig 2A and B). In contrast, naringenin 
treatment only resulted in a 50% inhibition of ERK1/2 phosphorylation at all 
reported time points. Lastly, all three treatments show a decrease in the amount of 
ERK after 4 days of treatment when compared to the control. However, this 
observed decrease is greater in the U0126 alone and combination treatments (Fig. 
2A and C).  
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B. 
 
 
  
17 
 
C. 
 
Figure 2. Naringenin is a Weak Inhibitor of ERK1/2 Phosphorylation. 
Tamoxifen resistant MCF-7 cells were grown in charcoal-stripped medium with 4-
OHT (100 nM) in the presence of Nar (200 µM), U0126 (10 µM) or a combination of 
the two for 24 h, 48 h, and 4 days. A. Protein lysates were prepared.  Lysates were 
subjected to SDS-PAGE and immunoblotted using antibodies against phospho-ERK 
1/2, ERK 1/2 and actin.  B. P-ERK to actin and C. ERK to actin were quantified using 
densitometric analysis by Quantity One software and are expressed as a percent of 
the control. The results are representative of 3 separate experiments.   
 
 
Naringenin and Inhibition of ERK1/2 Decreased Cell Proliferation 
Our lab as well as previous studies have reported that naringenin decreases 
cell proliferation [28, 30, 41].  This decrease in cell proliferation may be in part 
attributed to the observed inhibition on ERK1/2 expression and phosphorylation. 
ERK is a kinase involved in the MAPK pathway which promotes cell proliferation. 
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We wanted to determine if decreased cell proliferation is a direct result of ERK1/2 
inhibition in naringenin treated cells. Tamoxifen resistant MCF-7 cells were treated 
as previously stated with naringenin, U0126, or a combination of the two and 
assayed for cell proliferation. The effects of U0126 on cell proliferation were 
compared to those of naringenin. 
Cells from each treatment were prepared and cell density (cells/mL) was 
analyzed by flow cytometry. There was no significant difference in cell density in 
any of the treatment groups after 24 and 48 h when compared to the control. 
However, after 4 days of treatment all three groups showed a decrease in cell 
density. The U0126 treated cells had a slightly greater decrease in cell proliferation 
when compared to the control. Both U0126 and naringenin appear to elicit a similar 
effect on cell proliferation (Fig. 3).  
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Figure 3. Naringenin and U0126 Decrease Cell Density.  Tamoxifen resistant 
MCF-7 cells were grown in charcoal-stripped medium with 4-OHT (100 nM) in the 
presence of Nar (200 µM), U0126 (10 µM) or a combination of the two for 24 h, 48 h, 
or 4 days. Cell density (cells/mL) was determined by flow cytometry. Results are the 
means ± SEM of three separate experiments. Data were normalized to control.  
 
 
Inhibition of ERK1/2 Alone Does Not Account for Decreased Viability 
Naringenin has been reported to decrease cell proliferation as a result of 
decreased cell viability [31]. We wanted to determine if the effects on cell viability 
are a result of naringenin targeting and inhibiting ERK1/2. We treated tamoxifen 
resistant MCF-7 cells with U0126, naringenin, or a combination of the two as 
previously stated. Cells were collected from each treatment and prepared for flow 
cytometry analysis. Cell viability analysis revealed that both naringenin and U0126 
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reduced viability on day 4 to the same extent (Fig. 4A). However, when U0126 and 
naringenin were used in combination there appears to be an additive effect 
resulting in a greater decrease in cell viability. This same pattern was observed in 
cell death (Fig 4B). 
 
A. 
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B. 
 
Figure 4. Naringenin Does Not Inhibit Cell Viability by Inhibition of ERK. 
Tamoxifen resistant MCF-7 cells were grown in charcoal-stripped medium with 4-
OHT (100 nM) in the presence of Nar (200 µM), U0126 (10 µM) or a combination of 
the two for 24 h, 48 h, or 4 days.  A Cell viability and B. cell death were determined 
by flow cytometry. Results are the means ± SEM of three independent experiments. 
Data were normalized to control.  
 
 
Naringenin Induces Apoptosis 
 Previous studies reported that naringenin induces apoptosis through PARP 
and caspase activation in HeLa and MCF-7 cells [10, 31]. Our lab has shown that 
naringenin can induce apoptosis through the activation of caspase 7, which may 
explain the observed decrease in cell viability. In order to determine if induced 
apoptosis in naringenin treated cells is a result of ERK1/2 inhibition we examined 
the levels of apoptotic cells and the status of known apoptotic markers in U0126 
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treated cells. In this study we treated Tam-R MCF-7 cells with U0126, naringenin, or 
a combination of the two and determined the number of apoptotic cells to 
determine if the observed decrease in cell viability and proliferation correlated and 
whether inhibition of ERK1/2 alone was responsible for the effects of naringenin on 
viability. 
 Treated cells were prepared and analyzed by flow cytometry. Our findings 
show that there was an increase in apoptotic cells in all treatment groups when 
compared to the control (Fig. 5). Our data also indicated that there was no 
significant difference between the treatment groups over time. However, when 
compared to the control all three treatment groups show an increase in apoptotic 
cells beginning at 24 hours and continuing over each reported time point (Fig. 5). 
Our data for apoptotic cells correlates with the reported changes in cell viability and 
cell death where we saw a decrease in cell viability with a corresponding increase in 
cell death which can be explained by the increase in apoptosis. 
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Figure 5. Naringenin and U0126 Induce Apoptosis. Tamoxifen resistant MCF-7 
cells were grown in charcoal-stripped medium with 4-OHT (100 nM) in the 
presence of Nar (200 µM), U0126 (10 µM) or a combination of the two for 24 h, 48 h, 
or 4 days.  Mid-apoptotic cells were determined by flow cytometry. Results are the 
means ± SEM of three independent experiments. Data were normalized to control. 
 
 
To further analyze the mechanism of apoptosis we assayed the status of 
known apoptotic markers, caspase 7 and PARP, in naringenin and U0126 treated 
cells.  Our results indicate that both naringenin and U0126 lead to the 
cleaving/activation of PARP and caspase 7. After 24 h all three treatments show a 
decrease in caspase 7 expression. Naringenin maintains an approximate 20% 
decrease in caspase 7 at all the time points. The combination treatment and U0126 
alone show an almost complete activation of caspase 7 shown by the significant 
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decrease to no detectable expression of caspase 7 at 4 days (Fig. 6A and B). The 
combination treatment shows a greater effect than naringenin or U0126 alone at 
48h and 4 days (Fig. 6B) 
Next we examined the expression of PARP which is downstream of the 
activated caspases. Quantified data for PARP expression shows all three treatments 
decrease PARP expression. Naringenin again maintains a 20% decrease in PARP 
while U0126 resulted in an approximate 30% decrease at all sampling times when 
compared to the control. The combination treatment shows an approximately 50% 
decrease across all three time points when compared to the control.  Similar to the 
flow cytometry, the immunoblot analysis shows that the combination treatment has 
a greater effect than either naringenin or U0126 alone when compared to the 
control (Fig. 6).  The combination treatment effect appears to be an additive effect 
when compared to either naringenin or U0126 alone. 
 
  
25 
 
A. 
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26 
 
C. 
 
Figure 6. Naringenin and U0126 Decrease Expression of Apoptotic Markers. 
Tamoxifen resistant MCF-7 cells were grown in charcoal-stripped medium with 4-
OHT (100 nM) in the presence of Nar (200 µM), U0126 (10 µM) or a combination of 
the two for 24 h, 48 h, and 4 days. A. Protein lysates were prepared and subjected to 
SDS-PAGE and immunoblotted using antibodies against Caspase 7, PARP, and actin. 
B. Caspase 7 and C. PARP were quantified using densitometric analysis using 
Quantity One software and are expressed as a percent of the control. Results are the 
means ± SEM of three separate experiments.  Results are normalized to control. 
 
 
Naringenin Alone Influences Estrogen Receptor Localization 
 Next we examined the localization pattern of ERα. ER is found in both the 
cytoplasm and nucleus [6, 42–44].  ERα can be activated and enter the nucleus 
through either the binding of a ligand (estrogen) or phosphorylation [6, 8, 9, 11–13]. 
We have shown that naringenin impairs cytoplasmic ERα from entering the nucleus. 
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To determine if the effects of naringenin on ERα localization were a result of 
naringenin inhibiting ERK1/2 we treated cells with U0126, naringenin, or a 
combination of the two as previously stated and performed confocal microscopy as 
described in methods. The cells were incubated with antibodies against ERα.  
Similar to previous studies, our results show that the control cells (tamoxifen 
resistant MCF-7) have an even distribution of ERα in the cytoplasm and nucleus in 
all three time points (Fig. 7A. a-c and B). U0126 treated cells also show an even 
distribution of ERα at all the time points with no difference compared to the control 
(Fig. 7A. g-i and B).  In contrast, cells treated with naringenin and the combination 
treatment exhibited approximately 20-30% expression of ERα within the nucleus 
thus localizing more ERα within the cytoplasm compared to the control (Fig. 7 A. d-f; 
j-l and B). This data suggests that naringenin alone is responsible for the observed 
changes in ERα localization. 
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Figure 7. Inhibition of ERK Cannot Account for ERα Localization Change. 
Tamoxifen resistant MCF-7 cells were grown in charcoal-stripped medium with 4-
OHT (100 nM) in the presence of Nar (200 µM), U0126 (10 µM) or a combination of 
the two for 24 h, 48 h, and 4 days.  A. ERα localization was determined using 
confocal microscopy. B. Localization data was quantified using intensity parameters. 
The data is representative of three independent experiments. 
 
 
Naringenin has Multiple Targets 
 Naringenin can interact with proteins involved in kinase signaling pathways 
and ERα [28, 30, 42–44]. We hypothesized that the effects of naringenin on cell 
proliferation, viability, and apoptotsis could be explained by interacting and 
inhibiting the MAPK pathway through ERK1/2. Thus far, our data suggest that the 
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effects of naringenin cannot be explained by ERK1/2 inhibition alone. Furthermore, 
our data confirmed naringenin changes ERα localization and this effect is specific to 
naringenin. Thus we aimed to identify other possible molecular targets that would 
account for the anti-proliferative and pro-apoptotic effects of naringenin.  
To identify the targets of naringenin phage display libraries were screened. 
Phage display peptide libraries are randomly generated libraries in which 7 amino 
acid or 12 amino acid peptides are fused to the phage vector. We first had to 
immobilize naringenin to a surface. We coated 6cm plates with (100µg/mL) 
naringenin and tested the plates using mass spectrometry to determine whether 
naringenin bound to the plates. The analysis showed a strong naringenin (m/z 271) 
peak in the target solution that was added to the plate with an average signal of 
7.64e3.  After overnight incubation of the plate with the naringenin solution, the 
solution had an average signal of 5.17e3 naringenin. Lastly, the solution collected 
following multiple washes of the plate shows no detectable amount of naringenin 
which indicates that little to no naringenin was removed during the washing 
process. Although we are not able to directly detect naringenin on the plate, 
collectively, our findings suggest that naringenin bound the plates (Fig. 8).  
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Figure 8. Naringenin Binds to the Plate. Mass Spectrometry analysis was 
performed for the naringenin target solution added to the plates, the post-
incubation solution removed from the plates, and the solution removed from the 
plates following washes. The data is representative of three independent 
experiments. 
 
 
While phage screening is a known procedure it is an underutilized procedure 
for the identification of molecular targets in an unbiased manner. Thus, there are no 
reported studies using phage screening to identify all the possible targets of 
naringenin.  The process of identifying peptide sequences that bind to naringenin 
through the use of peptide-bound phage libraries requires several rounds of 
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selection and amplification of phage (Fig. 9). In our study we used both a 7 and 12 
amino acid library to identify the targets of naringenin. Both the 7 and 12 libraries 
have densities on the order of 109  independent clones. The 7 amino acid library 
provides a full range of all possible combinations of amino acids but there is less 
binding affinity and specificity. The 12 amino acid library provides increased 
specificity and binding affinity but less range because it does not have all the 
possible combinations of amino acids. The use of both libraries allows us to compare 
the sequence data and harness the benefits of both libraries [45].  
 
Figure 9. Overview of the Phage Screening Process. Naringenin was immobilized 
to the plates and washed before adding the desired phage library followed by 
incubation. The plates are washed before adding a naringenin solution to compete 
the bound phage creating the eluate. The eluate was amplified in ER2738 E.coli and 
the phage were isolated. The process was repeated 3 more times before selecting 
and purifying the phage for sequence analysis. 
33 
 
Following 4 rounds of amplification, phage were purified using a Qiagen prep 
kit and sequenced. There was no consensus among the identified sequences; 
however, there were a few repeated sequences such as HAIYPRH (Table 1). Our 
screen did not identify sequences reported by the manufacturer that are known to 
bind to plastic and are thus non-specific [46]. Our sequence data revealed that 
known targets of naringenin such as the estrogen receptor and cytochrome p450s 
were identified in our screen. Collectively, this provides further support that 
naringenin was immobilized to the plate and that this procedure was effective in 
identifying molecular targets of naringenin. 
 We identified multiple sequences of proteins involved in the ubiquitin 
pathway, specifically numerous E3 ubiquitin ligase enzymes. We also identified 
sequences present in several kinase proteins including proteins related to the MAPK 
signaling pathway, which was also expected because naringenin interacts with the 
MAPK pathway. Proteins involved in transcriptional regulation were also identified. 
Lastly, there were multiple proteins identified that contain zinc finger and coiled-
coil domains (Table 2).  
After further analysis of the identified proteins involved in the ubiquitin 
pathway we found that several of the E3 ligases are overexpressed in cancers such 
as breast cancer. E3 ubiquitin ligase XIAP is involved in antiapototic signaling by 
targeting caspases and is found to be overexpressed in cancers [39, 47]. F-box/WD 
repeat-containing protein 7 has been reported to be overexpressed in breast cancer 
and targets cyclin E [39]. Furthermore, E3 ubiquitin protein ligase HUWE1 is 
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overexpressed in breast cancer and targets p53 thus promoting cell growth and 
antiapoptosis signaling [39, 48] (Table 3).  E3 ubiquitin-protein ligases Itchy and 
DTX1 have been reported as negative regulators of NOTCH 1, a protein involved in 
the Hippo signaling pathway which promotes cell proliferation and differentiation 
[49, 50]. Lastly, it is important to note that E3 ligase UBR5 has been reported to be 
disrupted in cancers (overexpressed in breast cancer) and is a regulator of 
ERα protein levels and transcriptional activity and thus cell proliferation [51]. 
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Table 1.  Identified Sequences from Phage Screening. 
7-mer Library 12-mer Library 
Y S I P K S S L E S H Y T Q A S Y T Q (2) 
A Q P A L Q R K L H I S K D H I Y P T 
E D L R W W T H S T A G W L H S Y M I (2) 
L P L T P L P (2) N M E L H P H S L P R P 
M V P K W V A M A H T H T P S V T I T (2) 
H A I Y P R H (3) L V F P V T S D T I L F 
G H W A A L V  
W Q T S P P F  
H E K P T R H  
W E A H A P L  
G P M L A R G  
W P T L Q W A  
G N T P S R A  
L P L Y I K S  
K I P I A L S  
N N T M M H H  
T F I N P S H  
S S F P P L L  
(#)-indicates a sequence that was selected more than once 
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Table 2. Most Frequent Categories of Proteins from Phage Screening. 
Families of Proteins Examples 
Ubiquitin Pathway E3 ubiquitin-protein ligase UBR3  
UBR5  
HUWE1  
XIAP 
Itchy  
DTX1 
DTX4  
TRIM23 
F-box/LRR-repeat protein 13 
F-box/WD repeat-containing protein 7  
F-box/WD repeat-containing protein 10 
Ubiquitin-conjugating enzyme E2 O 
Kinase MAP4K4 
MAP3K7 
MAPK7 
serine/threonine-protein kinase LATS1 
 PLK1  
 OSR1 
kinase suppressor of Ras 2 (2) 
Receptors G-protein coupled receptor 1 and 98 
Steroid hormone receptor ERR1 
Zinc Finger Zinc finger protein 30, 266, 423 , 404, 526 (2), 808, 462 
Transcription Regulation Nuclear receptor corepressor 1 
Nuclear receptor coactivator 2 
Transcription initiation factor TFIID 
transcriptional-regulating factor 1 
Transcription factor COE1 
Histone deacetylase complex subunit SAP130 
Mediator of RNA polymerase II transcription  
RNA polymerase II-associated protein 1 
Forkhead box protein P1, P2, I3 
Drug Metabolism Cytochrome P450 1A2 
 2R1 
 26C1  
 2W1 
Coiled-Coil Coiled-coil domain-containing protein 84, 141, 142(2)  
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Table 3. Ubiquitin Pathway Proteins with Correlating Domains and Function. 
Class Sequence Protein Domain Function 
Ring N M E L H P H S L P R P 
 
 
 
 
Y S I P K S S 
 
 
 
 
 
H A I Y P R H 
E3 ub-protein 
ligase DTX1 & 
DTX4 
 
 
E3 ub-protein 
ligase ZNRF2  
E3 ub-protein 
ligase DTX1  
 
 
E3 ub-protein 
ligase XIAP 
Directly 
downstream Ring 
domain and in DTX 
domain 
 
100 bp upstream 
Ring domain 
~15 bp downstream 
WWE domain 
 
 
BIR domain-inhibits 
caspases thus 
apoptosis 
Ubiquitination of 
MEKK1, NOTCH 1 
regulation 
 
 
 
 
Ubiquitination of 
MEKK1, NOTCH 1 
regulation 
 
Overexpressed in 
cancers-Stops 
apoptotic cell death 
F-box H S T A G W L H S Y M I 
 
 
 
 
M A H T H T P S V T I T 
 
 
 
 
G H W A A L V 
F-box/WD 
repeat-
containing 
protein 13 
 
F-box/WD 
repeat-
containing 
protein 7 
 
F-box/WD 
repeat-
containing 
protein 10 
~100 bp Upstream 
F-box  
 
 
 
~50 bp upstream F-
box 
 
 
 
~100 bp upstream 
WD40 domain – 
protein-protein 
interaction 
 
 
 
 
 
Mutations in 
ovarian and breast 
cancer- 
ubiquitination of 
cyclin E 
UBR K L H I S K D H I Y P T 
 
 
 
 
E D L R W W T 
E3 ub-protein 
ligase UBR3 
 
 
 
E3 ub-protein 
ligase UBR5 
 
 
 
 
 
N-terminal 
Ubquitin-associated 
domain 
Regulates APE1 
required for DNA 
repair and genome 
stability 
 
Disrupted in 
cancers-increased in 
breast cancer 
regulator of 
ERα protein levels 
and transcriptional 
activity thus cell 
proliferation 
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HECT Y S I P K S S 
 
 
 
 
 
 
 
 
 
 
H A I Y P R H 
 
 
E3 ub-protein 
ligase HUWE1  
 
 
 
 
 
 
 
 
 
E3 ub-protein 
ligase Itchy  
 
N-terminus end - 
domain of unknown 
function 
 
 
 
 
 
 
 
 
C-terminal HECT 
catalytic domain for 
E2 conjugation 
Overexpressed in 
breast and 
colorectal cancer. 
Major target 
p53/TP53 tumor 
suppressor 
promotes cell 
growth and 
antiapoptosis 
 
 
Negative regulator 
of Large Tumor 
Suppressor 1 
(LATS1) of Hippo 
Signaling Pathway- 
tumorogenesis, 
differentiation and 
renewal. 
Ubiquitination of 
NOTCH 1 
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CHAPTER IV 
DISCUSSION 
 
 
Tamoxifen is the most widely used ER antagonist therapy employed to treat 
ER+ breast cancers [16, 19]. Tamoxifen arrests cell growth leading to a cytostatic 
state by binding ERα and thus preventing estrogen from binding. While ERα bound 
by tamoxifen can still translocate into the nucleus it is unable to properly recruit co-
activators required for transcription. Unfortunately, it has been widely reported that 
after long term use of tamoxifen cells can become resistant and overcome the 
cytostatic state created by tamoxifen [16, 19]. Resistant cells can evade the effects of 
tamoxifen and achieve ERα activation through kinase signaling pathways such as 
MAPK pathway [20, 22]. Our lab has shown that naringenin can inhibit these kinase 
signaling pathways and interact with ERα. However, the specific molecular targets 
responsible for the effects of naringenin are unknown.  
 The effects of naringenin and other flavonones have been studied in relation 
to glucose uptake, as endocrine disruptors as well as their use as a possible 
therapeutics in multiple cancers [6, 29, 32, 43]. It has been reported that naringenin 
can bind/interact with the ER [42, 43]. It has also been suggested that naringenin 
can affect kinase signaling pathways. However, the primary targets of naringenin 
have not been identified. 
40 
 
Our studies suggest that all of the effects observed in naringenin treated cells 
cannot be fully explained by the inhibition of ERK1/2 phosphorylation. Therefore, 
this suggests that naringenin targets other proteins to elicit its effects on decreased 
cell viability. Although our data shows that both naringenin and U0126 decrease cell 
viability (Fig. 4) and induce apoptosis (Fig. 5 and 6) to a similar extent, when used in 
combination there is a greater decrease that appears to be additive. Our results do 
not show a significant change in cell density (approximate 50% decrease) at 30 h as 
shown in previous reports  [52]. However, this difference could be a result of our 
studies using Tam-R MCF-7 cells compared to MCF-7 cells used in previous studies.  
Furthermore, when phosphorylated and total ERK were analyzed, naringenin 
was a weaker inhibitor of phosphorylation and expression than U0126 (Fig. 2). Our 
results showed a 40-50% decrease in phoshorylated ERK1/2 in naringenin treated 
cells (Fig. 2B) which is comparable to previous studies using MCF-7 breast cancer 
cells [43]. Our data suggests that naringenin and U0126 could be eliciting these 
effects through different mechanisms or by naringenin interacting with different 
target proteins. Naringenin could be targeting something further upstream from 
MEK or another protein involved in the regulation of this pathway. This would 
result in our observed additive effect in the combination treatments. 
 Since it has been reported that naringenin interacts with the ER and it has 
previously been shown that naringenin changes the localization pattern of the ER, 
we tested U0126 to see if naringenin was eliciting this change through direct 
interaction or through a kinase pathway. Our data demonstrated that U0126 did not 
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alter the ER localization pattern when compared to the untreated cells. Therefore, 
naringenin could be directly interacting with the ER to prevent cytoplasmic ER from 
entering the nucleus or it could be targeting proteins involved in ER localization and 
regulation. This effect is specific to naringenin and cannot be explained by inhibiting 
ERK1/2 expression and/or phosphorylation. 
 Our studies show that in the absence of estrogen, naringenin is still able to 
inhibit ERK1/2 phosphorylation and change ERα localization. This suggests that the 
effects of naringenin are not dependent on estrogen. Futhermore, the inhibition of 
ERK1/2 phosphorylation does not explain the effects on cell viability nor the change 
in ERα localization. Therefore, we focused our studies on identifying other 
molecular targets of naringenin. Our screen of phage display libraries identified 
amino acid sequences that interact with naringenin. An analysis of these sequences 
identified various families of proteins including known targets of naringenin such as 
cytochrome P450s and ER (Table 2). However, there was an unexpected abundance 
of proteins related to the ubiquitin pathway such as E3 ligases (Table 2). This 
suggests that naringenin could potentially be targeting E3 ubiquitin ligases and 
altering their activity. E3 ligases are enzymes involved in the ubiquitin system that 
ubiquitinate proteins for degradation thus effecting cell signaling pathways involved 
in cell proliferation and survival [37–39, 53]. Therefore, if naringenin is effecting E3 
ligase activity this could lead to changes in protein expression of factors such as p53, 
cyclins, caspases, and membrane receptors involved in cell proliferation and 
viability [39, 47, 54]. Naringenin could also be utilizing the E3 ligase system to 
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regulate ERα. The E3 ligase UBR5 was identified as a putative target of naringenin 
(Table 2) and UBR5 has been reported to regulate ERα protein levels as well as 
affect ERα target genes and estrogen-mediated cell proliferation in breast cancer 
cells [51].   
 Studies have shown that naringenin affects multiple processes including 
metabolism, cell proliferation, apoptosis, and glucose uptake [6, 28–30, 52]. 
Furthermore, our studies in tamoxifen resistant breast cancer cells, naringenin has 
been shown to affect the MAPK pathway, ERα, cell proliferation, cell viability, and 
apoptosis. Collectively, this suggests that the effects of naringenin could be the 
result of naringenin targeting a more global protein such as E3 ligases which leads 
to multiple effects. Overall, our studies open the door for further investigation into 
the use of naringenin in the treatment of tamoxifen resistant, ER+ breast cancers. 
Further research is needed to verify the significance of the identified proteins as 
targets of naringenin. Also future studies will need to determine how naringenin is 
interacting with E3 ligases, how and if that further inhibits ERα function and 
localization, and if E3 ligase interaction is also related to the decrease in MAPK 
signaling.  
Our studies suggest that naringenin could be a possible therapeutic to target 
E3 ligases that are overexpressed or uncontrolled in cancer cells. Many therapies 
target a specific protein to inhibit one pathway such as tamoxifen which directly 
binds the ER. While treatments like tamoxifen are effective, cells can become 
resistant because the targeted pathway can be by-passed with other signaling 
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pathways. However, our data suggests naringenin is able to affect multiple pathways 
without completely inhibiting them. This partial inhibition may suggest that 
naringenin has a low affinity for the target protein which would be desirable for 
treatment purposes. Partial inhibition would still allow essential pathways to 
function. This indicates that naringenin has the potential to be an effective therapy 
especially if used in combination with other drugs such as tamoxifen. 
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